Study finds GLP‐1 RAs reduced 4‐year mortality by 24% compared to SGLT2 inhibitors in people with SMI
The mortality gap for people with bipolar disorder, major depressive disorder, and schizophrenia is mainly due to cardiovascular disease. Individuals with serious mental illness (SMI) have a life expectancy of 10 to 25 years shorter than the general population. This is partly due to psychopharmacotherapy‐related metabolic effects and systemic disparities in prevention and treatment, leading to the need to find interventions that address cardiovascular outcomes and metabolic risk.
Publication Details
- Journal
- The Brown University Psychopharmacology Update
- Published
- 2026-11-14
- DOI
- https://doi.org/10.1002/pu.31517
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00